RxDoctor Payments Data

Mark Ramos, MD

Cardiovascular Disease · Sarasota, FLNPI 1336339811

Payments from drug & device makers

$326,806in general payments, 2019–2025

Across 166 payments — averaging $1968.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$306K
  • E.r. Squibb & Sons, L.L.C.$15K
  • Novartis$3K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$598
  • Merck$263
  • Irhythm Technologies, Inc.$194
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$1,8006%
  • Speaking & faculty fees$23,33879%
  • Travel & lodging$6362%
  • Food & beverage$3,68713%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$326,806 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,328,200
Medicare patients
6,930
Services billed
18,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,707$2,180,415
VyndamaxTafamidis26$610,804
EntrestoSacubitril/Valsartan316$415,815
XareltoRivaroxaban328$398,776
FarxigaDapagliflozin Propanediol183$189,965
Repatha SureclickEvolocumab164$173,229
JardianceEmpagliflozin108$108,936
Repatha SyringeEvolocumab61$49,972
Repatha PushtronexEvolocumab33$28,857
Praluent PenAlirocumab21$15,839
Metoprolol Succinate973$13,866
Atorvastatin Calcium1,488$13,681
Rosuvastatin Calcium889$10,594
MultaqDronedarone Hcl12$9,606
Flecainide Acetate186$8,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Vyndamax$159$2,791,2191,733 claims
NovartisEntresto$3,170$415,815316 claims
Johnson & JohnsonXarelto$179$398,776328 claims
AstraZenecaFarxiga$62$189,965183 claims
Boehringer IngelheimJardiance$59$108,936108 claims
Sanofi-aventis U.S. LLCMultaq$25$9,60612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →